As NfL is increased in many neurodegenerative diseases, including several multisystemic ataxias19 and atypical parkinsonian conditions,9 the biomarker value of NfL levels lie in their ability to reflect disease severity and progression and in their potential as stratification biomarkers for MSA drug trials. The gene discussed is NEFL; the disease is neurodegenerative disease.